| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28a271df64c0adc233ea7302734c9dcb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 |
| filingDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_567a9c4d23adada4af060fb79909466e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c106a24bfa95dd0576c88ef7cee6ccd |
| publicationDate |
2019-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019358201-A1 |
| titleOfInvention |
Modified doxorubicin compositions and methods |
| abstract |
The inventors unexpectedly discovered that aldoxorubicin lacks cardiotoxicity in patients treated with aldoxorubicin alone or in combination with ifosfamide/mesna. Notably, no evidence of cardiac toxicity of aldoxorubicin was found, even at doxorubicin equivalent cumulative doses of up to 10,000 mg/m2. |
| priorityDate |
2018-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |